Rigrodsky & Long, P.A. Announces Investigation Of Complete Genomics, Inc. Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Complete Genomics, Inc. (“Complete Genomics” or the “Company”) (NASDAQ GM: GNOM) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by BGI-Shenzhen (“BGI”) in a transaction valued at approximately $117.6 million.

Click here to learn more: http://www.rigrodskylong.com/investigations/complete-genomics-inc-gnom.

Under the terms of the proposal, public shareholders of Complete Genomics will receive $3.15 per share in cash for each share of Complete Genomics they own.

The investigation concerns whether Complete Genomics’ board of directors failed to adequately shop the Company and obtain the best possible value for Complete Genomics’ shareholders before entering into an agreement with BGI. According to Yahoo! Finance, at least one analyst has set a price target for Complete Genomics stock at $5.00 per share.

If you own the common stock of Complete Genomics and purchased your shares before September 17, 2012, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530 toll free at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/complete-genomics-inc-gnom.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010

If you liked this article you might like

3 Biotech Stocks Under $10 Surging Higher

5 Biotech Stocks Under $10 Set to Soar

Insiders Trading GEVA, GNOM, VPRT, HSON

Complete Genomics Stock Falls On Unusually High Volume (GNOM)

Complete Genomics Stock Hits New 52-Week Low (GNOM)